Loading organizations...
§ Private Profile · San Diego, CA, USA
Tentarix Biotherapeutics is a technology company.
Tentarix Biotherapeutics develops novel multi-specific biologic therapies for complex diseases. The company employs proprietary platforms, VH-Select™ and FunctionSeq™, to discover and engineer differentiated treatments that leverage validated biology. These technologies enable the precise design of biologics with tailored functionality, aiming to improve therapeutic outcomes in areas with high unmet medical need.
Dion Madsen co-founded Tentarix Biotherapeutics, bringing substantial experience in biotechnology. The company emerged from the insight that advanced protein engineering could unlock new therapeutic possibilities by creating biologics with highly specific and potent targeting capabilities. This foundational principle guides Tentarix in overcoming the limitations often associated with traditional monotherapies, fostering the development of more effective interventions.
Tentarix’s therapeutic pipeline is designed to serve patients afflicted with challenging conditions, including various oncology indications and autoimmune diseases. The company’s long-term vision is to deliver highly effective and well-tolerated medicines by precisely modulating critical disease pathways. They are committed to translating their innovative platform into a robust suite of biologics that will significantly advance patient care.
Tentarix Biotherapeutics has raised $85.0M across 2 funding rounds.
Tentarix Biotherapeutics has raised $85.0M in total across 2 funding rounds.
Tentarix Biotherapeutics is a San Diego-based biotechnology company developing conditionally active multispecific biologics that activate only in diseased tissue, improving efficacy and reducing toxicity for hard-to-treat targets in oncology, immuno-oncology, and autoimmune diseases.[1][2] The company serves patients with complex therapeutic needs by addressing persistent issues like systemic toxicity from non-conditional biologics and manufacturing challenges for cytokines, using proprietary platforms VH-Select™ (stabilized human VH scaffold for binder discovery) and FunctionSeq™ (mammalian display with NGS for precise conditional activation).[2] With partnerships including multi-year deals with AbbVie and Gilead Sciences, $135M in total funding (including a recent $35M round), and a wholly owned pipeline advancing to the clinic, Tentarix demonstrates strong growth momentum.[1][3][5]
Tentarix was founded by biotech veterans Srini Akkaraju and Paul Kang, leveraging their deep expertise in biologics innovation.[4] Akkaraju, a serial entrepreneur and investor, founded Samsara BioCapital after roles at Sofinnova Ventures, New Leaf Ventures, and Genentech; he also serves on boards like Seagen and Intercept Pharmaceuticals.[4] Kang brings over 20 years in antibody technologies from ImmGenics, Abgenix (acquired by Amgen), and Amgen, including key contributions to SLAM and XenoMouse platforms.[4] The idea emerged from their drive to solve industry pain points in conditional biologics, leading to the Tentacles™ platform; early traction came via partnerships, notably three multi-year collaborations with Gilead in August 2023 for oncology and inflammatory diseases.[3][5] The team's collective decades in biologics— including CSO Thomas Bumol's advancement of over 100 molecules like Trulicity® and Mounjaro® at Eli Lilly—has fueled rapid progress toward clinical milestones.[4]
Tentarix stands out in biologics R&D through:
Tentarix rides the wave of precision biologics and tissue-selective therapies, capitalizing on advances in multispecific antibodies and NGS-driven discovery amid rising demand for safer oncology and autoimmune treatments.[2][3] Timing is ideal as biologics face scrutiny for toxicity—e.g., cytokines' instability—and post-pandemic focus on immune modulation grows, with market forces like Big Pharma partnerships (Gilead, AbbVie) accelerating validation.[1][3][5] By enabling "intelligent" biologics for validated but elusive pathways, Tentarix influences the ecosystem, pushing competitors toward conditional designs and fostering innovation in hard-to-drug areas like immuno-oncology.[2]
Tentarix is primed for clinic entry with near-term milestones, expanded partnerships, and funding firepower, potentially yielding first-in-class therapies in oncology and autoimmunity.[1][2] Trends like AI/NGS integration in discovery and demand for high-index biologics will propel growth, evolving Tentarix from platform innovator to clinical leader—much like how early multispecific pioneers reshaped the field. Watch for data readouts and new deals to cement its transformative edge in reimagining biologics.[1][3]
Tentarix Biotherapeutics has raised $85.0M across 2 funding rounds. Most recently, it raised $35.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $35M Series B | Allyson Tighe | Access Biotechnology, Andreessen Horowitz, BackBone Ventures, Brendan Bulik Sullivan, Pfizer Venture Investments, Samsara BioCapital, Versant Ventures, Daniel Vasella, Reinhard Ambros, Shinichiro Fuse, Gilead Sciences | Announced |
| Oct 1, 2021 | $50M Series A | Samsara BioCapital, Versant Ventures | Access Biotechnology, Amplitude VC, Andreessen Horowitz, BackBone Ventures, Brendan Bulik Sullivan, Pfizer Venture Investments, Daniel Vasella, Reinhard Ambros, Shinichiro Fuse | Announced |
Tentarix Biotherapeutics has raised $85.0M in total across 2 funding rounds.
Tentarix Biotherapeutics's investors include Allyson Tighe, Access Biotechnology, Andreessen Horowitz, BackBone Ventures, Brendan Bulik-Sullivan, Pfizer Venture Investments, Samsara BioCapital, Versant Ventures, Daniel Vasella, Reinhard Ambros, Shinichiro Fuse, Gilead Sciences.